Business Wire

NY-DOUXMATOK

14.9.2021 15:02:06 CEST | Business Wire | Press release

Share
DouxMatok and Hi-Food Partner to Deliver Great Tasting Nutritional Sugar Reduced Solutions

Today, DouxMatok (Israel/USA) and Hi-Food (Italy), two food-tech pioneers leading the development of innovative ingredients, announce a partnership to deliver a complete end-to-end nutritional solution for food manufacturers. DouxMatok’s first-of-its-kind sugar-based sugar reduction solution, Incredo® Sugar , alongside Hi-Food’s semi-solid fiber of natural origin, Meltec® , will allow food brands to address sugar reduction in food products without compromising on taste, texture, sweetness or nutrition.

Incredo Sugar, which officially launched last year and is now commercially available in the U.S., enables up to 50% sugar reduction in food products. The ingredient allows room for nutritional ingredients such as fibers and plant-based proteins, creating a natural fit for a joint effort with Hi-Food’s Meltec, an innovative semi-solid ingredient similar to syrup that is based on vegetable fibers of natural origin. In addition to enriched fiber content, Meltec improves structural properties in food products, is neutral in taste and does not alter odors or colors.

“In partnership with Hi-Food, we’ll be able to deliver more than just a specialty ingredient for great tasting sugar reduction solutions to food brands,” said DouxMatok’s Chief Technology Officer, David Tsivion. “We can provide a full nutritional platform that delivers the scalability and functionality needed for food developers and food production, and the sweetness and mouthfeel that consumers have come to expect.”

The collaborative effort between DouxMatok and Hi-Food addresses one of the most common challenges of existing solutions on the market — maintaining sweetness and other sugar functionalities while avoiding the aftertastes often associated with sugar substitute bulking solutions and addressing other missing sugar functionalities. Research and application development teams at both companies have been working together for over a year to test Incredo® Sugar and Meltec® in combination as pillars to full nutritional solutions in various applications.

“We’re really impressed with the collaborative work of our team and our partners at DouxMatok, and we’re confident in the ability of these combined ingredients to provide a solution that the market is lacking,” said Emanuele Pizzigalli, R&D Officer and co-founder at Hi-Food. “Sugar reduction is a key priority for food manufacturers across the globe, and we’re committed to helping them address this challenge through the use of our fibers with Incredo Sugar.”

The companies have developed product prototypes across a range of applications, including cakes, cookies, chocolate, candy, protein bars, energy bars, snacks, and more. The unique combination of these ingredients also provides an added sustainability value for the food industry as a whole, helping to reduce the environmental impact of overconsumption of sugar, and at the same time exploiting the use of high-quality raw materials from well controlled legumes and cereals supply chains. Products utilizing DouxMatok and Hi-Food’s full nutritional solution are expected to launch in early 2022.

To learn more about DouxMatok and Incredo® Sugar, please visit douxmatok.com or incredosugar.com , or follow along on LinkedIn . For more information about Hi-Food and Meltec® , please visit hifood.it , or follow along on LinkedIn . Organizations interested in working with DouxMatok and Hi-Foods can reach out to partnerships@douxmatok.com and info@hifood.it to learn more about product development opportunities.

About Incredo® Sugar

Recognized as a special mention in the ‘Best Inventions of 2020’ by TIME, Incredo® Sugar is the flagship product of DouxMatok , a global food-tech company pioneering the development of efficient nutrition and flavor technologies and enabling tastier and healthier consumption of foods. Incredo® Sugar is a first-of-its-kind, sugar-based sugar reduction solution that improves the efficiency of sugar delivery to the sweet taste receptors and enhances the perception of sweetness enabling substantial sugar reduction without compromising taste, mouthfeel, or texture. Based on real cane sugar, this breakthrough, patented sugar reduction solution enables food manufacturers to develop delicious, better-for-you formulations that deliver great taste experiences and enhance nutritional values of sweet food products while reducing sugar. In April 2021, DouxMatok launched its first product, limited edition Incredo Spreads in two flavors via shop.incredosugar.com . For more information, please visit incredosugar.com , or follow along on Facebook and Instagram .

About DouxMatok

DouxMatok is pioneering the development of efficient nutrition and flavor delivery technologies of food products. Patented through 24 granted patents, its sugar reduction solution, Incredo® Sugar, maximizes the efficiency of sugar delivery to the sweet taste receptors and enhances the perception of sweetness, enabling substantial sugar reduction without compromising taste, mouthfeel, or texture. Independent consumer and expert sensory panel tests have confirmed that, when using Incredo® Sugar, it is possible to reduce 30%-50% of the sugar levels in a wide range of food and snack products while retaining consumer preferences. For more information, please visit douxmatok.com , or follow along on LinkedIn .

About Meltec®

Meltec® – award winning and patented – semi-solid innovative ingredient is rich in fiber and guarantees excellent texturing and bulking properties without sweetening. Produced in Italy, this ingredient made by ingredients of natural origin (corn and chickpeas) is neutral in taste and smell and has less than 1% of sugars. Apparently similar to honey or glucose syrup, Meltec® is suitable for all sugar-free / low-sugar applications, acts as a humectant, texturizing, thickening, filling, cryoprotectant agent and reducing freezing point in a wide range of foods: typical applications include bars, granolas, cakes, ice-creams, sauces and fillings. For more information, please visit hifood.it .

About Hi-Food

Hi-Food was founded in 2012 in Parma, at the heart of Italy’s “Food Valley,” by a group of entrepreneurs with a proven track record in the natural ingredients sector. Over the years, the Company has developed deep expertise and applications knowledge in producing and using natural products, such as new fibers, proteins, gluten-free nucleus, clean label and plant-based systems to create customized functional solutions for conventional and disruptive food industry (traditional bakery, gluten free, gastronomy, sauces, fillings, dessert, ice cream, beverage, new plant-based foods). The R&D team are on-hand to answer questions and solve issues about shelf-life, stability, sugar/salt/fat reduction, egg replacement, fiber/protein enrichment, structure improvement or many other needs which are suitable for its ingredients, and customer finished product. Hi-Food operates research and production facilities in Italy and is expanding its footprint with a state-of-the-art new production plant and R&D application center in Parma. For more information, please visit hifood.it or follow along on LinkedIn .

Link:

ClickThru

Social Media:

https://www.facebook.com/incredosugar/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye